CD36 and breast cancer: Studies have shown that resistance to HER2-targeted therapies in HER2+ BC is often associated with the abnormal activation of mesenchymal HER2+ cancer stem cells, Team Serenella M Pupa found that a consistent enrichment of CD36 in HER2+ breast cancer stem cells from all tested resistant cell models that mechanistically occurs via Wnt signaling pathway activation (74).